Overview

Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery. The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.

Full Product Details

Author:   Cheorl-Ho Kim, PhD (Professor and Chair, Department of Biological Sciences, College of Science, Sungkyunkwan University, South Korea)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
Weight:   0.450kg
ISBN:  

9780443458446

ISBN 10:   0443458448
Pages:   375
Publication Date:   01 June 2026
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Forthcoming
Availability:   Not yet available  
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Table of Contents

Section I. Cholinergic drugs for Alzheimer’s Disease: Mechanisms, emerging and future evolution 1. Introduction 2. Current hypothesis for Alzheimer’s Disease progression 3. Neurotransmitter (NT) systems and peripheral nerve system (PNS) 4. ACh receptors in Ach transmission 5. Choline esterase 6. Cholinergic ACh, AChE, and its inhibitors 7. Classification of ChE inhibitors by binding mode 8. Classification of ChE inhibitors by activation mechanism 9. Clinical status of ChE inhibitors 10. ChE inhibitors 11. Forthcoming generation of AChE inhibitors 12. Hybrid inhibitors 13. AChE-targeted drugs for Alzheimer’s Disease treatment 14. Cholinergic neuromuscular junction and its blocking agents (blockers) 15. Non-adrenergic and non-cholinergic (NANC) neurotransmitters 16. Protein kinase inhibitors for treatment of Alzheimer’s Disease 17. Inhibition of cholinergic inflammation via AChE inhibitor interaction with α4β2 nAChE and α7nAChR, not AChE enzyme inhibition 18. NMDA and non-NMDA receptor antagonism for Alzheimer’s Disease treatment 19. Challenges in recent Alzheimer’s Disease therapeutic approaches 20. Identification and application of biomarkers for Alzheimer’s Disease 21. Artificial Intelligence (AI)-assisted Alzheimer’s Disease target and drug discovery 22. Conclusion and perspectives Section II. Natural alkaloidal and non-alkaloidal anti-AChE and anti-Alzheimer’s Disease compounds in the symptomatic intimation of Alzheimer’s Disease 23. Introduction 24. Current bioactive molecules in Alzheimer’s Disease therapy 25. Emerging lead compounds from natural bioactive molecules for Alzheimer’s Disease therapy 26. Natural anti-AChE compounds for Alzheimer’s Disease therapy 27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities 28. Conceptual search for MTDs of natural plant compounds for multifactorial Alzheimer’s Disease therapy 29. AChE inhibitors of daily-consumable cereals and food resources 30. Conclusion and perspectives Section III. Marine AChE inhibitors for the symptomatic treatment of Alzheimer’s Disease 31. Introduction 32. Localization, structure and cellular function of AChE 33. AChE inhibitors from marine resources 34. Non-ChE inhibitory anti-Alzheimer’s Disease compounds 35. Emerging concept of dual-target drug (DTD) and multi-target drug (MTD) in Alzheimer’s Disease pathology and promising Alzheimer’s Disease drugs 36. Conclusion and perspectives

Reviews

Author Information

Dr. Cheorl-Ho Kim is Professor and Chair of the Department of Biological Sciences, College of Science, Sungkyunkwan University in South Korea. He is also Professor at the Samsung Advanced Institute of Health Science and Technology (SAIHST), South Korea. Dr. Kim obtained his MS and PhD from the University of Tokyo, Japan. Prior academic appointments include Genome Program Head, Korea Research Institute of Bioscience and Biotechnology, and Chairman of the Department of Biochemistry and Molecular Biology, Dongguk University, South Korea. Dr. Kim’s research interests include neurological health, neuroinflammation, oncogenesis, and cancer metastasis.

Tab Content 6

Author Website:  

Countries Available

All regions